Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.68 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL326876 | 0.98 | SIGMAR1 (0.70) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL28255325 | 0.97 | SIGMAR1 (0.72) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL7156078 | 0.92 | SIGMAR1 (0.75) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL42099 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL9114797 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL9114800 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL11415206 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42100 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL1608168 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42098 | 0.84 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | SLC6A4 4168/4885SIGMAR1 1769/4885TAAR1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.